Zacks Investment Research on MSN
Will Keytruda remain the driving force behind Merck's Q2 performance?
Merck’s MRK blockbuster PD-1 inhibitor, Keytruda, approved for several types of cancer, is its key top-line driver, ...
Many think the next standard cancer treatment will pair two innovations.
Merck’s (NYSE:MRK) leading drug, Keytruda, has shown remarkable recent growth—a success story with a foreseeable conclusion. The pharmaceutical company’s strong performance has been largely driven by ...
Merck (MRK) stock is in focus as the company posts a late-stage trial win for anti-PD-1 therapy, Keytruda, in endometrial cancer. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results